Siglec-2/CD22
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P20273 |
---|---|
Species | Human |
Sequence | Asp20-Arg687 |
Purity | > 95% as analyzed by SDS-PAGE > 95% as analyzed by HPLC |
Endotoxin Level | ≤ 1 EU/ µg of protein by LAL method |
Biological Activity | Immobilized Human Siglec2 at 0.5 µg/ml (100 µl/Well). Dose response curve for Biotinylated Anti-Siglec2 Ab with the EC50 of 0.2 µg/ml determined by ELISA. |
Expression System | Expi293 |
Formulation | Lyophilized from a 0.22 µm filtered solution in PBS, pH 7.4. Normally 5 % trehalose is added as protectant before lyophilization. |
Reconstitution | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in distilled water up to 100 µg/ml. |
Storage & Stability | Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Avoid repeated freeze-thaw cycles. |
Gene ID | 933 |
---|---|
Other Names | B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14, CD22, CD22 {ECO:0000303|PubMed:1691828, ECO:0000312|HGNC:HGNC:1643} |
Target Background | CD22, or cluster of differentiation-22, is a molecule belonging to the SIGLEC family of lectins. It is found on the surface of mature B cells and to a lesser extent on some immature B cells. CD22 a member of the immunoglobulin superfamily. CD22 functions as an inhibitory receptor for B cell receptor (BCR) signaling. It is also involved in the B cell trafficking to Peyer's patches in mice. |
Name | CD22 {ECO:0000303|PubMed:1691828, ECO:0000312|HGNC:HGNC:1643} |
---|---|
Function | Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow (PubMed:34330755, PubMed:8627166). Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration (PubMed:20172905). Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling (PubMed:8627166). If this negative signaling from is of sufficient strength, apoptosis of the B-cell can be induced (PubMed:20516366). |
Cellular Location | Cell membrane; Single-pass type I membrane protein |
Tissue Location | B-lymphocytes. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.